1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

28 Jun 2025
Admin
News Article

KalVista & Pendopharm Partners to Commercialise Sebetralstat for Hereditary Angioedema

Overview

KalVista Pharmaceuticals has entered into a licensing agreement with Pendopharm to support the commercialisation of its oral hereditary angioedema (HAE) treatment, sebetralstat, in Canada.

About Sebetralstat

Sebetralstat is an investigational oral treatment designed for on-demand use in people with HAE.
It works by inhibiting plasma kallikrein, which plays a role in the biochemical pathway that causes the swelling attacks typical of the condition.
Regulatory applications have been submitted for patients aged 12 years and older, with further studies under way to assess its use in children aged 2 to 11.

About the medical condition: hereditary angioedema

HAE is a rare genetic condition caused by a deficiency or malfunction of the C1 esterase inhibitor protein, leading to excessive activation of the kallikrein-kinin system.
This results in sudden, often painful swelling in various parts of the body.
Most currently available on-demand treatments must be administered via injection, whereas sebetralstat, if approved, could become the first oral option, potentially improving convenience and quality of life for patients.

Agreement term

Under the agreement, Pendopharm will take responsibility for managing the regulatory approval process and commercial rollout of sebetralstat in the Canadian market.
The partnership forms part of KalVista’s strategy to expand global access to the therapy. Financial details of the agreement have not been disclosed.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!